跳转至内容
Merck
  • SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.

SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.

The Journal of cell biology (2017-12-13)
Manuel Viotti, Catherine Wilson, Mark McCleland, Hartmut Koeppen, Benjamin Haley, Suchit Jhunjhunwala, Christiaan Klijn, Zora Modrusan, David Arnott, Marie Classon, Jean-Philippe Stephan, Ira Mellman
摘要

Epithelial-to-mesenchymal transition is implicated in metastasis, where carcinoma cells lose sessile epithelial traits and acquire mesenchymal migratory potential. The mesenchymal state is also associated with cancer stem cells and resistance to chemotherapy. It might therefore be therapeutically beneficial to promote epithelial identity in cancer. Because large-scale cell identity shifts are often orchestrated on an epigenetic level, we screened for candidate epigenetic factors and identified the histone methyltransferase SUV420H2 (KMT5C) as favoring the mesenchymal identity in pancreatic cancer cell lines. Through its repressive mark H4K20me3, SUV420H2 silences several key drivers of the epithelial state. Its knockdown elicited mesenchymal-to-epithelial transition on a molecular and functional level, and cells displayed decreased stemness and increased drug sensitivity. An analysis of human pancreatic cancer biopsies was concordant with these findings, because high levels of SUV420H2 correlated with a loss of epithelial characteristics in progressively invasive cancer. Together, these data indicate that SUV420H2 is an upstream epigenetic regulator of epithelial/mesenchymal state control.

材料
货号
品牌
产品描述

Sigma-Aldrich
Anti-KMT5C antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution